ViiV’s Dolutegravir Dual Therapy Works for Both First-Line & Maintenance Treatment
ViiV’s Dolutegravir Dual Therapy Works for Both First-Line & Maintenance Treatment
Findings from the GEMINI and TANGO studies, reported at the 10th International AIDS Society...
An HIV Injectable Regimen Comes of Age
Without the Pill Box?
The First Long-Acting Injectable Regimen for Individuals Living with HIV Comes of Age
by Mel Baker
A funny thing happened on the way to...
FDA Approves New HIV Treatments
The U.S. Food and Drug Administration (FDA) has approved pharmaceutical giant Merck’s Delstrigo and Pifeltro for the treatment of HIV-1 infection in adult patients...
Under One Roof: ViiV Healthcare Strives for New HIV Treatments
If we think of HIV as carrying a kind of a malware that takes over human T cells and turns them into a machine...
Dual Regimens in Trials Show Promise
The Power of Two
Dual regimens show promise in clinical trials
by Chael Needle
At the International AIDS Conference in Amsterdam last July, ViiV Healthcare shared its...
Use of HIV Preexposure Prophylaxis May Increase Use of Primary Care
A new study reveals that patients who use PrEP (Pre-exposure Prophylaxis ), a combination of the antiretroviral medications emtricitabine and tenofovir called Truvada, to...
Janssen Announces FDA Approval of SYMTUZA
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on July 18, 2018 that the U.S. FDA has approved the use of SYMTUZA, the...
TANGO Study Starts
In February 2018, ViiV Healthcare announced the start of a forty-eight-week phase III study designed to determine whether adults with HIV-1 who have achieved...
Immunochemical Engineering of Cell Surfaces: A Conversation with Dr. Jia Xie
Countdown
Researcher Jia Xie discusses a cutting-edge treatment in development
by Dann Dulin
Block HIV by using the body’s own immune cells? Is it truly possible?!
Well, such...
FDA Approves First Two-Drug Once-Daily Single-Pill HIV Regimen
On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved the first-ever two-drug once-daily single-pill regimen for the maintenance treatment of adults...
LATEST POSTS
NMAC Launches the National HIV and Aging Advocacy Network
NMAC Launches the National HIV and Aging Advocacy Network
On September 16, 2021, NMAC and its Strong and Healthy Program launched the National HIV and...
